$3250 | Single User
$4650 | Site License
$5650 | Global License

Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated
[Lowest Price Guaranteed: $3,250]

Published by AnalystView: 01 Jul 2020 | 270553 | In Stock
Related Topics: COVID , Drug , FDA , GlaxoSmithKline , Hypertension , Novartis , Pfizer , Pharmaceuticals , Pulmonary

Introduction

REPORT HIGHLIGHT Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016-2027

"REPORT HIGHLIGHT

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 6.41 billion by 2019 with growth rate of 5.6%.

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

The sudden challenges created by the ongoing COVID-19 outbreak is captured effectively to exhibit the long term growth projections in the Pulmonary Arterial Hypertension (PAH) Market report. The top growth segments and marginal growth sectors of the Pulmonary Arterial Hypertension (PAH) Market are identified with precision for a better growth perspective.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The years considered for the study are:

Historical Year – 2016 to 2018

Base Year – 2019

Estimated Year – 2020

Projected Year – 2027

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

Prostacyclin and Analogs

Soluble Guanylyl Cyclase (SGC) Stimulators

Endothelin receptor antagonist (ERA)

Phosphodiesterase-5

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

Table of Contents
for Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated

  • "TABLE OF CONTENT

    1. PULMONARY ARTERIAL HYPERTENSION MARKET OVERVIEW

    1.1. Study Scope

    1.2. Assumption and Methodology

    2. EXECUTIVE SUMMARY

    2.1. Key Market Facts

    2.2. Geographical Scenario

    2.3. Companies in the Market

    3. PULMONARY ARTERIAL HYPERTENSION KEY MARKET TRENDS

    3.1. Market Drivers

    3.1.1. Impact Analysis of Market Drivers

    3.2. Market Restraints

    3.2.1. Impact Analysis of Market Restraints

    3.3. Market Opportunities

    3.4. Market Future Trends

    4. PULMONARY ARTERIAL HYPERTENSION INDUSTRY STUDY

    4.1. Porter’s Analysis

    4.2. Market Attractiveness Analysis

    4.3. Regulatory Framework Analysis

    4.4 PULMONARY ARTERIAL HYPERTENSION MARKET: COVID-19 IMPACT ANALYSIS

    4.4.1 Pre-COVID-19 Impact Analysis

    4.4.2 Post-COVID-19 Impact Analysis

    4.4.3 Top Performing Segments

    4.4.4 Marginal Growth Segments

    4.4.5 Top Looser Segments

    4.4.6 Marginal Loss Segments

    5. PULMONARY ARTERIAL HYPERTENSION MARKET LANDSCAPE

    5.1. Market Share Analysis

    6. PULMONARY ARTERIAL HYPERTENSION MARKET – BY DRUG CLASS

    6.1. Overview

    6.2. Prostacyclin and Analogs

    6.2.1. Overview

    6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    6.3. Soluble Guanylyl Cyclase (SGC) Stimulators

    6.3.1. Overview

    6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    6.4. Endothelin receptor antagonist (ERA)

    6.4.1. Overview

    6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    6.5. Phosphodiesterase-5

    6.5.1. Overview

    6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7. PULMONARY ARTERIAL HYPERTENSION MARKET– BY GEOGRAPHY

    7.1. Introduction

    7.2. North America

    7.2.1. Overview

    7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.2.3. U.S.

    7.2.3.1. Overview

    7.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.2.4. Canada

    7.2.4.1. Overview

    7.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.3. Europe

    7.3.1. Overview

    7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.3.3. France

    7.3.3.1. Overview

    7.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.3.4. Germany

    7.3.4.1. Overview

    7.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.3.5. Rest of Europe

    7.3.5.1. Overview

    7.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.4. Asia Pacific (APAC)

    7.4.1. Overview

    7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.4.3. China

    7.4.3.1. Overview

    7.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.4.4. India

    7.4.4.1. Overview

    7.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.4.5. Rest of APAC

    7.4.5.1. Overview

    7.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.5. Rest of the World

    7.5.1. Overview

    7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.5.3. Latin America

    7.5.3.1. Overview

    7.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    7.5.4. Middle East and Africa

    7.5.4.1. Overview

    7.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

    8. KEY VENDOR ANALYSIS

    8.1. Pfizer, Inc.

    8.1.1. Company Overview

    8.1.2. SWOT Analysis

    8.1.3. Key Developments

    8.2. GlaxoSmithKline

    8.2.1. Company Overview

    8.2.2. SWOT Analysis

    8.2.3. Key Developments

    8.3. Novartis

    8.3.1. Company Overview

    8.3.2. SWOT Analysis

    8.3.3. Key Developments

    8.4. Bayer

    8.4.1. Company Overview

    8.4.2. SWOT Analysis

    8.4.3. Key Developments

    8.5. Merck

    8.5.1. Company Overview

    8.5.2. SWOT Analysis

    8.5.3. Key Developments

    *Client can request additional company profiling as per specific requirements

    9. 360 DEGREE ANALYSTVIEW

    10. APPENDIX

    10.1. Research Methodology

    10.2. Abbreviations

    10.3. Disclaimer

    10.4. Contact Us"

List Of Tables
in Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated

List of Tables

Table 1 List of Acronyms

Table 2 Key Market Facts, 2016-2027

Table 3 Market Drivers: Impact Analysis

Table 4 Market Restraint: Impact Analysis

Table 5 Market Opportunity: Impact Analysis

Table 6 PEST Analysis

Table 7 Porter’s Five Forces Analysis

Table 8 Company Market Share Analysis

Table 9 Global Pulmonary Arterial Hypertension Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016-2027, (US$ Billion)

Table 10 Pulmonary Arterial Hypertension Market, by Drug Class, 2016-2027 (USD Billion)

Table 11 Pulmonary Arterial Hypertension Market, by Geography, 2016-2027 (USD Billion)

Table 12 North America Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 13 U.S. Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 14 Canada Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 15 Europe Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 16 France Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 17 Germany Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 18 Asia Pacific Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 19 China Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 20 India Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 21 Latin America Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

Table 22 MEA Pulmonary Arterial Hypertension Market, 2016-2027 (USD Billion)

List Of Figures, Charts and Diagrams
in Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated

List of Figures

Figure 1 Research Methodology

Figure 2 Research Process Flow Chart

Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)

Figure 4 Regulatory Framework Analysis

Figure 5 Pulmonary Arterial Hypertension Market, by Drug Class, 2016-2027 (USD Billion)

Figure 6 Pulmonary Arterial Hypertension Market, by Geography, 2016-2027 (USD Billion)

Additional Details

Publisher

AnalystView

Publisher Information

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.



These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.



We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.



We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.



It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Reference

270553 | AV199

Number of Pages

216

Report Format

PDF

AnalystView Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Idiopathic Pulmonary Fibrosis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]
IntroductionGain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (I...
01 Mar 2016 by FirstWord Pharma USD $995 More Info
Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Pulmonary Inflammation Global Clinical Trials Review, H2, 2015
Pulmonary Inflammation Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
25 Nov 2015 by Global Data USD $2,500 More Info
Physician Views: Assessing competition in the idiopathic pulmonary fibrosis market
Scope Late 2014/early 2015 witnessed a flurry of activity in the idiopathic pulmonary fibrosis (IPF)...
01 May 2015 by FirstWord Pharma USD $695 More Info
Idiopathic Pulmonary Fibrosis: KOL Insight
IntroductionRoche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only...
01 May 2015 by FirstWord Pharma USD $7,900 More Info
Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
20 Apr 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views: The idiopathic pulmonary fibrosis (IPF) market – let battle commence
Scope The battle for market share in the US idiopathic pulmonary fibrosis (IPF) market is one that w...
28 Oct 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development landscapes?
Scope Data presented at last week's American Thoracic Society (ATS) conference confirmed that InterM...
27 May 2014 by FirstWord Pharma USD $695 More Info
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
20 Jan 2014 by FirstWord Pharma USD $7,495 More Info

This report is published by AnalystView

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Download Free Report Summary PDF

Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...